PNC Financial Services Group
AKTX

PNC Financial Services Group’s Akari Therapeutics AKTX Stock Holding History

PNC Financial Services Group’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14
Closed -$12K – 4431
2022
Q2 		$12K Sell
14
-1
-7% -$887 ﹤0.01% 3710
2022
Q1 		$14K Hold
15
– – ﹤0.01% 3723
2021
Q4 		$18K Hold
15
– – ﹤0.01% 3582
2021
Q3 		$20K Hold
15
– – ﹤0.01% 3489
2021
Q2 		$21K Hold
15
– – ﹤0.01% 3438
2021
Q1 		$32K Hold
15
– – ﹤0.01% 3204
2020
Q4 		$22K Hold
15
– – ﹤0.01% 3294
2020
Q3 		$21K Hold
15
– – ﹤0.01% 3196
2020
Q2 		$26K Buy
+15
New +$22.9K ﹤0.01% 3084

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
BMCM
Bryn Mawr Capital Management Philadelphia, Pennsylvania $2.06B AUM 19.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Financial Services Group's AKTX Position: Q3 2022 in Review

PNC Financial Services Group sold out of Akari Therapeutics (AKTX) in Q3 2022, closing a stake of 14 shares — an estimated $12K sold.

PNC Financial Services Group first reported a position in AKTX in Q2 2020 and held it in 9 quarters. The position peaked at $32K in Q1 2021. 14 funds tracked by Wall St. Rank hold AKTX as of Q3 2022.

  • PNC Financial Services Group reported no remaining Akari Therapeutics position as of Q3 2022 after selling out during the quarter.
  • PNC Financial Services Group sold 14 Akari Therapeutics shares in Q3 2022, an estimated $12K.
  • PNC Financial Services Group first reported a position in Akari Therapeutics in Q2 2020 and held it in 9 quarters.
  • PNC Financial Services Group's Akari Therapeutics position peaked at $32K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Akari Therapeutics as of Q3 2022.

Based on PNC Financial Services Group's 13F filing for Q3 2022, filed 10 Nov 2022.